PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 37, Issue 7, 1996, Pages 1451-1458

  Seregard, Stefan ^a   Oskarsson, Margareta ^a   Spångberg, Berit ^a  

^a ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

PC 10 antibody; posterior uveal melanoma; predictive accuracy; prognosis; receiver operator characteristic (ROC) curve

Indexed keywords

MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER SURGERY; ENUCLEATION; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AUTOANTIGENS; CELL COUNT; CELL DIVISION; EYE ENUCLEATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; REPRODUCIBILITY OF RESULTS; ROC CURVE; SURVIVAL RATE; UVEAL NEOPLASMS;

EID: 0029884893     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma: A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand. 1995;73:340-344.
2. McLean IW, Foster WD, Zimmerman LE. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502-509.
3. Gamel JW, McLean IW. Quantitative analysis of the Callender classification of uveal melanoma cells. Arch Ophthalmol. 1977;95:686-691.
4. Gamel JW, McLean IW, Greenberg RA, Zimmerman LE, Lichtenstein SJ. Computerized histologic assessment of malignant potential: A method for determining the prognosis of uveal melanomas. Hum Pathol. 1982;13:893-897.
5. Huntingdon A, Haugan P, Gamel J, McLean I. A simple cytologic method for predicting the malignant potential, of intraocular melanoma. Pathol Res Pract. 1989;185:631-634.
6. McCurdy J, Gamel J, McLean I. A simple, efficient, and reproducible method for estimating the malignant potential of uveal melanoma from routine H & E slides. Pathol Res Pract. 1991;187:1025-1027.
7. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary uveal melanoma. Hum Pathol. 1992;23:1298-1305.
8. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389-1398.
9. Pe'er J, Rummelt V, Mawn L, Hwang T, Woolson RF, Folberg R. Mean of the ten largest nucleoli, microcirculation, and prognosis of ciliochoroidal melanomas. Ophthalmology. 1994;101:1227-1235.
10. Quinn CM, Wright NA. The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables. J Pathol. 1990;160:93-102.
11. Gass JDM. Comparison of uveal melanoma growth rates with mitotic index and mortality. Arch Ophthalmol. 1985;103:924-931.
12. McLean IW, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:45-58.
13. Silverberg SG. Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumours of the uterus. Hum Pathol. 1976;7:451-454.
14. Burns B, Curry RH, Bell MEA. Morphological features of prognostic significance in uterine smooth muscle tumors: A review of eighty-four cases. Am J Obstet Gynecol. 1979;135:109-114.
15. Hall PA, Levison DA. Assessment of cell proliferation in histological material. J Clin Pathol. 1990;43:184-192.
16. Mooy CM, de Jong PTVM, van der Kwast TH, Mulder PGH, Jager MJ, Ruiter DJ. Ki-67 immunostaining in uveal melanoma: The effect of pre-enucleation radiotherapy. Ophthalmology. 1990;97:1275-1280.
17. Pe'er J, Gnessin H, Shargal Y, Livni N. PC-10 immunostaining of proliferating cell nuclear antigen in posterior uveal melanoma: Enucleation versus enucleation postirridiation groups. Ophthalmology. 1994;101:56-62.
18. Taylor CR, Shi S-R, Chaiwun B, Young I, Imam SA, Cote RJ. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: Androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 1994;25:263-270.
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
20. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
21. Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990;96:121-129.
22. Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem. 1989;264:13856-13864.
23. Landberg G, Roos G. Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis. Cancer Res. 1991;51:4570-4574.
24. Wisjman JH, van Dierendonck J-H, Keijzer R, van de Velde CJH, Cornelisse CJ. Immunoreactivity of proliferating cell nuclear antigen compared with bromodeoxyuridine incorporation in normal and neoplastic rat tissue. J Pathol. 1992;168:75-83.
25. Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferations with evidence of deregulated expression in some neoplasms. J Pathol. 1990;162:285-294.
26. Seregard S. Cell proliferation as a prognostic indicator in conjunctival malignant melanoma. Am J Ophthalmol. 1993;116:93-97.
27. Takahashi H, Strutton GM, Parsons PG. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody. Histopathology. 1991;18:221-227.
28. Woods AL, Hall PA, Shephed NA, et al. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology. 1991;19:21-27.
29. Schofield JB, Mansi J, Camplejohn RS, Lane DP, Fisher C. Proliferating cell nuclear antigen and S-phase fraction in endometrial stromal sarcoma. J Clin Pathol. 1992;45:664-667.
30. Yu CC-W, Hall PA, Fletcher CDM, et al. Haemangiopericytomas: The prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology. 1991;19:29-33.
31. Jain S, Filipe M, Hall PA, Waseem N, Lane DP, Levison DA. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol. 1991;44:655-659.
32. Yu CC-W, Fletcher CDM, Newman CDM, et al. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (Ag-NOR) staining, and histological grading in gastrointestinal stromal tumours. J Pathol. 1992;166:147-152.
33. Swerdlow SH, Westermann CD, Pelstring RD, Saboorian MH, Williams ME. Growth fraction in centrocytic and follicular cell lymphomas: Assessment in paraffin sections with a proliferating cell cell nuclear antigen antibody and morphometric correlates. Hum Pathol. 1993;24:540-546.
34. Mangham DC, Rowlands DC, Newbold KM, Reynolds GM, Fielding JWL, Hallissey MT. Expression of proliferating cell nuclear antigen (PCNA) in gastric carcinoma: No evidence for prognostic value. J Clin Pathol. 1994;47:473-474.
35. Thomas M, Noguchi M, Kitagawa H, Kinoshita K, Miyazaki I. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol. 1993;46:525-528.
36. Ghazvini S, Kroll S, Char DH, Lattman J, Frigillana H. Comparative anaysis of proliferating cell nuclear antigen, bromodeoxyuridine and mitotic index in uveal melanoma. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1995;36:S415.
37. Ward TP, McLean IW, Roberts AO. Expression of proliferating cell nuclear antigen (PCNA) in primary uveal melanoma. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1994;35:1926.
38. Bell PB, Rundqvist I, Svensson I, Collins VP. Formaldehyde sensitivity of a GFAP epitope, removed by extraction of the cytoskeleton with high salt. J Histochem Cytochem. 1987;35:1375-1380.
39. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissue: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741-748.
40. Wolf H, Dittrich KL. Detection of proliferating cell nuclear antigen in diagnostic histopathology. J Histochem. Cytochem. 1992;40:1269-1273.
41. Greenwell A, Foley JF, Maronpot RR. An enhancing method for immunohistochemical staining of proliferating cell nuclear antigen in archival rodent tissues. Cancer Lett. 1991;59:251-256.
42. Haerslev T, Jacobsen GK. Microwave processing for immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) in formalin-fixed and paraffin-embedded tissue. APMIS. 1994;102:395-400.
43. Seregard S. Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma. J Clin Pathol. 1996;49:338-342.
44. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285-1293.
45. Pritchard ML, Woosley JT. Comparison of two prognostic models predicting survival in patients with malignant melanoma. Hum Pathol. 1995;26:1028-1031.